Oramed Pharmaceuticals Announces Publication in the Journal of Diabetes Science and Technology
Results Describe Preclinical Trials Demonstrating Retained GLP-1 Analog Activity When Delivered With Oramed's Oral Drug Delivery Formulations
JERUSALEM, December
1, 2010/PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc.
(OTCBB: ORMP.OB) ( http://www.oramed.com), a developer of oral drug
delivery solutions, announces a publication in the Journal of
Diabetes Science and Technology's November issue describing
evaluation of the company's glucagon-like peptide- (GLP-1) analog
formulation (ORMD-0901) in regulating glucose excursions in animal
models.
GLP-1 and its analogs
harbor significant therapeutic potential for management of Type 2
diabetes mellitus through their broad physiological impact on
glucose regulation-related mechanisms. However, the naturally
secreted GLP-1 is degraded within minutes and in cases of impaired
release or activity, is typically substituted by exogenously
supplied, long-lived analogues. To date, these drugs are only
available in injectable forms, leading to systemic effects upon
administration as well as unsatisfactory patient compliance and
adherence.
With the objective of
offering a safer, more practical and physiologically relevant
alternative, Oramed has applied its oral drug delivery platform to
the GLP-1 analog family. High sugar-content meals were delivered to
animals in the presence or absence of ORMD-0901, followed by close
monitoring of blood glucose levels. Specific formulations were
found to effectively blunt expected glucose surges in both
ORMD-0901-treated porcines and canines. The two animal models used
for testing the performance of ORMD-0901, indicated retained drug
activity when delivered using Oramed's oral drug delivery
platform.
Oramed has already
embarked on clinical testing of its ORMD-0901 product to assess the
formulation's safety and efficacy in healthy individuals. Further
testing and development are expected to significantly contribute to
current diabetes control options and success rates.
In addition to an
oral GLP1 analog capsule, the Company's flagship product is an oral
insulin capsule. The Company is currently working towards
submission of an IND to the FDA for a Phase 2 clinical trial.
To view the article
abstract please click on the link below:
http://www.journalofdst.org/November2010/PDF/Abstract/VOL-4-6-ORG20-ELDOR-ABS
TRACT.pdf
(Due to the length of
this URL, it may be necessary to copy and paste this hyperlink into
your Internet browser's URL address field. Remove the space if one
exists.)
About Oramed
Pharmaceuticals
Oramed
Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via
injection. Oramed is seeking to revolutionize the treatment of
diabetes through its patented flagship product, an orally
ingestible insulin capsule currently in Phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years
of research performed by top research scientists at Jerusalem's
Hadassah Medical Center. The Company's corporate and R&D
headquarters are based in Jerusalem.
For more information,
please visit http://www.oramed.com
Safe Harbor
Statement
Some of the
statements contained in this press release are forward-looking
statements which involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or
achievements of the company, or industry results, to be materially
different from any future results, performance or achievements
expressed or implied by such forward looking statements, including
the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our
product candidates; competition from other pharmaceutical or
biotechnology companies; and the company's ability to obtain
additional funding required to conduct its research, development
and commercialization activities. Please refer to the company's
filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results,
performance or achievements of the company to differ materially
from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any
forward-looking statements.
Company and Investor Relation Contacts:
Oramed Pharmaceuticals
Tara Horn
Cell: +972-54-334-318
Office: +972-2-566-0001
Email: tara@oramed.com
Source: Oramed Pharmaceuticals Inc.
Company and Investor
Relation Contacts: Oramed Pharmaceuticals, Tara Horn, Cell:
+972-54-334-318, Office: +972-2-566-0001, Email:
tara@oramed.com
Posted: December 2010
